LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
Javier Cortés, S-B. Kim(University of Ulsan), W-P. Chung(National Cheng Kung University Hospital), S-A. Im(Seoul National University Hospital), Y.H. Park(Samsung Medical Center), Roberto Hegg(Centro de Pesquisas Oncológicas), Minjung Kim(Yonsei University), L-M Tseng(Taipei Veterans General Hospital), Vanessa Petry(Instituto do Câncer do Estado de São Paulo), C-F. Chung(Koo Foundation Sun Yat-Sen Cancer Center), Hiroji Iwata(Aichi Cancer Center), E.P. Hamilton(Tennessee Oncology), Giuseppe Curigliano(University of Milan), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), C. Lee(Daiichi Sankyo (United States)), Y. Liu(Daiichi Sankyo (United States)), Jillian Cathcart(Daiichi Sankyo (United States)), Emarjola Bako(Daiichi Sankyo (United States)), Sunil Verma(AstraZeneca (United States)), Sara A. Hurvitz(UCLA Jonsson Comprehensive Cancer Center)
Cited by 96
Abstract
Related Papers
No related papers found
Powered by citation graph analysis